Novartis

Glenmark pharma launches generic version of Novartis' heart failure drug

Opens floodgates for more generic launches; 40 new brands expected

Breather for Natco in Novartis cardiac drug case from Delhi High Court

May open floodgates for Indian drugmakers to launch the generic version of the drug as early as next week

Novartis signs world's first licensing deal for high-priced cancer drug

The oral drug, nilotinib, is used to treat chronic myeloid leukemia and may be made in Egypt, Guatemala, Indonesia, Morocco, Pakistan, the Philippines, and Tunisia

Novartis to cut up to 8,000 jobs globally to save $1 bn by 2024

As part of the organisational overhaul unveiled in April, Novartis said that the cost cuts would be mainly from removing overlapping structures

Cash-flush Novartis launches new share buyback of up to $15 bn

The buyback is funded through the $20.7 billion the Swiss drugmaker raised by selling its nearly one-third voting stake in Roche back to its cross-town rival last month

Novartis cuts uneasy 20-year ties to Roche with $20.7-bn voting stake sale

The company is booking a capital gain of about $14 billion on the investment at a time when the cost of acquisitions in pharma have been soaring

Novartis Q1 sales, profit miss analyst expectations amid Covid-19 impact

Swiss drugmaker Novartis on Tuesday said first-quarter core net income fell 4%

Novartis, Molecular Partner team up on coronavirus candidates treatment

Novartis has licenced global rights to two Molecular Partners antiviral drugs that have potential to treat Covid-19 patients, the two companies said

Novartis lifts 2020 forecast as drugmakers see hospitals coping with Covid

ZURICH (Reuters) - Novartis joined rivals Merck, Johnson & Johnson and Roche in predicting the worst of the pandemic may be over for drugmakers, amid signs healthcare systems have learned how to cope with surging infections without shutting down all services.

Top headlines: CBI, ED to charge GVK Group, Biden promises on H1-B & more

Here are the top headlines of the day

Novartis pays $729 mn to settle US charges that it paid doctors kickbacks

It will also pay $51.25 million to resolve charges it funnelled money through three charitable foundations to cover co-payments of Medicare patients so they would purchase its drugs

Coronavirus vaccine not coming for at least 2 years: Novartis global CEO

A vaccine must be widely tested in humans before being administered to hundreds of millions, say experts

Novartis confirms 2020 outlook; sales, profit up amid Covid-19 outbreak

Core net income rises to $3.55 billion from $2.8 billion in 2019, against the average analyst forecast in a Refinitiv poll of $3.17 billion

Novartis scraps sale of assets including Covid-19 drug to Aurobindo Pharma

Novartis is donating 130 million hydroxychloroquine doses to support efforts against the epidemic, though the European Union has so far said there is no proof it works.

Novartis CEO says Malaria drug biggest hope against coronavirus: Newspaper

Malaria, lupus and arthritis drug hydroxychloroquine is under clinical trials, says Novartis.

Novartis, Merck, Allergan raise US prices, 445 drugs to cost more in 2020

That is above the average of 404 drug price increases in the first three days of January over the past five years

Switzerland is country partner for BioAsia event on February 17-19

BioAsia is an annual event in which stakeholders in the lifesciences sector discuss new innovations and explore possibility of business collaborations in the sector

Eris Lifesciences acquires trademark Zomelis from Novartis AG for $13 mn

Used in the treatment of type 2 diabetes, Zomelis comes under a new class of anti-diabetic drugs known as DPP 4 inhibitors

Novartis's $90 million Swiss factory to help solve cell therapy bottleneck

Basel-based Novartis sees cell and gene therapies eventually contributing about 15% of its revenue

Novartis takes on Sanofi, Amgen with $9.7-bn takeover of heart drug maker

Novartis shares were seen up 0.2%, premarket indicators showed.